Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.74 |
| ▸ | BLVRB | P30043 | 1/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 13/20 | 0.59 |
| ▸ | NPC1 | O15118 | 12/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RARA | P10276 | 1/20 | 0.52 |
| ▸ | RARB | P10826 | 1/20 | 0.52 |
| ▸ | RARG | P13631 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60632 | 0.91 | HDAC6 (0.74) | MAOABLVRBHDAC6RAB9ANPC1 | |
| SCHEMBL30153181 | 0.88 | HDAC6 (0.77) | MAOABLVRBHDAC6RAB9ANPC1 | |
| SCHEMBL60215 | 0.88 | HDAC6 (0.77) | MAOABLVRBHDAC6RAB9ANPC1 | |
| SCHEMBL60083 | 0.87 | HDAC6 (0.80) | MAOABLVRBHDAC6RAB9ANPC1 | |
| SCHEMBL19131020 | 0.86 | NPC1 (0.58) | MAOABLVRBHDAC6RAB9ANPC1 | |
| SCHEMBL60680 | 0.86 | MAOA (0.74) | MAOABLVRBHDAC6RAB9ANPC1 | |
| SCHEMBL60369 | 0.86 | MAOA (0.74) | MAOABLVRBHDAC6RAB9ANPC1 | |
| Ataluren SCHEMBL29365205 | 0.85 | MAOA (1.00) | MAOABLVRBHDAC6RAB9ANPC1 | |
| Ataluren SCHEMBL29360108 | 0.85 | MAOA (1.00) | MAOABLVRBHDAC6RAB9ANPC1 | |
| Ataluren SCHEMBL29361641 | 0.85 | MAOA (1.00) | MAOABLVRBHDAC6RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10959988-B2 | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid for the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190231754-A1 | CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID FOR THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2019-08-01 | — | — | US | disclosed |
| US-10300047-B2 | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid for the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300047-B2 | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid for the treatment of disease | UPF1, RNMT, RBM17 | MAOA 2373/4885BLVRB 2669/4885HDAC6 371/4885 |
| US-20190231754-A1 | CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID FOR THE TREATMENT OF DISEASE | UPF1, RNMT, RBM17 | MAOA 2373/4885BLVRB 2669/4885HDAC6 371/4885 |
| US-10959988-B2 | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid for the treatment of disease | UPF1, RNMT, RBM17 | MAOA 2373/4885BLVRB 2669/4885HDAC6 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.